Author Archives: BPI Staff

Waters adding automation lab tech by buying Andrew Alliance

Waters Corporation will add an automated software system and robotics technology through the acquisition of Swiss biotech firm Andrew Alliance. Life sciences chromatography and measurement company Waters Corporation has not divulged the financial details of the deal, but a company spokesman said it significantly bolsters its lab tech portfolio through the addition of automated technologies. “Andrew Alliance’s cloud-native software platform and user interface dramatically improves the use of automation technology, enabling more scientists to realize the advantages of repeatability and…

Symbiosis ups aseptic capacity by 25%; plans to expand further in 2020

The expansion addresses sustained demand particularly for cell and gene therapy services, says Scottish CDMO Symbiosis. Contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services has completed a £1.5 million ($1.8 million) expansion at its site in Stirling, UK – about 40 miles northwest of Scottish capital Edinburgh. The investment increases the firm’s output by about 25%, CEO Colin MacKay told this publication, and will help feed the demand aseptic GMP manufacturing (fill/finish) services. “Expansion of the business relates specifically…

AGC Bio looks to tap growing plasmid DNA market

AGC Bio’s expanded offering at its site in Heidelberg will serve a plasmid DNA (pDNA) space growing at 20 % CAGR, the CDMO says. Contract development manufacturing organization (CDMO) AGC Bio has completed a pDNA manufacturing process improvement project at its site in Heidelberg, Germany. The firm says this will enable the extension of the offer in hosts and plasmids with scales of 1 L to 10 L for High Quality pDNA, and will be easy to scale up to…

Liminal divesting Prometic Bioseparations to KKR in $100m deal

Investment firm KKR is set to acquire Prometic Bioseparations, the chromatography and bioprocessing business of Liminal BioSciences. Global biotech firm Liminal BioSciences, which changed its name in September from Prometic Life Sciences, has announced the sale of Prometic Bioseparations (PBL) to KKR. The investment firm will pay £45 million ($58 million), with up to £32 million ($42 million) more upon closing of the deal. PBL offers chromatography columns and services for the biomanufacturing industry. Its Evolve Process column range offers…

Mesa Labs picks up Gyros in $180m bio QC deal

Swedish immunoassay and peptide synthesis firm Gyros Protein Technologies has been acquired by Mesa Laboratories in a deal worth $180 million (€163 million). Colorado-based quality control instruments and consumables firm Mesa Laboratories says it is increasing its presence in the discovery, development and manufacturing of biotherapeutics through the acquisition, adding Gyros’ immunoassay platform. “We completed a business combination (the “GPT Acquisition”) whereby we acquired the common stock of Gyros Protein Technologies Holding AB (“GPT”), a company whose business provides Immunoassay…

Aspen alert! Novartis buys assets for $330m in Japan boost

Novartis division Sandoz has acquired the Japanese business of Aspen Global Incorporated (AGI), bolstering its biosimilar and generics presence in the region. South African pharma firm Aspen Holdings opened the Japanese subsidiary Aspen Japan K.K. in May 2015, with an aim bring its oncology, immunosuppressant, anti-inflammatory, hypertension, and anticoagulant products to the market. Today, Sandoz, the generics and biosimilar division of Swiss Biopharma firm Novartis, has announced it will pay an initial €300 million ($330 million) to buy shares in…

Thermo to add culture media production capacity at Scotland site by 2021

Thermo Fisher Scientific will spend $24 million (€22 million) to up culture media capacity at its Inchinnan, Scotland facility. The firm said it will add large-volume liquid manufacturing capacity for cell culture media by 2021. Cory Stevenson, president of Thermo Fisher’s bioproduction business, said increased biopharmaceutical industry demand prompted the investment. “More and more customers are outsourcing their liquid manufacturing to ensure the highest quality while delivering efficiency.” “This investment will expand capabilities and expertise at our existing cell culture…

Cognate buys Cobra to boost gene therapy CDMO capabilities

Cell therapy CDMO Cognate Bioservices will add plasmid DNA and viral vector capabilities through the acquisition of Swedish manufacturer Cobra Biologics. Memphis, Tennessee-based contract development and manufacturing organization (CDMO) Cognate has entered into an agreement to acquire Cobra for an undisclosed fee, led by existing Cognate investor EW Healthcare Partners. The deal adds to Cognate’s presence in the regenerative medicine space by bringing on board plasmid DNA and viral vector manufacturing capacity and expertise, complementing its own autologous and allogeneic…

CAR-T at a crossroad as industry looks to allogeneic

As cell therapies move through the clinic towards commercialization, respondents to a KNect365 industry survey are beginning to look to allogeneic – or off-the-shelf – products as the next big thing. Almost 200 people contributed to the Cell Therapy Analytics Report from KNect365, revealing their current position within the burgeoning cell and gene therapy space and offering up their thoughts and predictions for the future. The majority worked within companies developing oncology products, and the largest group – 41% –…

Big M&A: Alexion in $930m Achillion buy, UCB bids $2.1bn for Ra

In a big week for Big Pharma M&A, Alexion has agreed to buy Factor D inhibitor developer Achillion and UCB will add a late-stage FcRn targeting antibody through its acquisition of Ra Pharmaceuticals. Alexion Pharmaceuticals, which itself has been in the news recently as a potential target for M&A-hungry Amgen, announced today it has agreed to buy clinical-stage biopharmaceutical company Achillion Pharmaceuticals for approximately $930 million (€842 million). The deal adds oral small molecule Factor D inhibitors to treat people…